Simplified Summary
VIP is a member of the glucagon/secretin peptide superfamily that acts through two G-protein coupled receptors, VPAC1 and VPAC2, expressed on smooth muscle, immune cells, neurons, and peripheral tissues. Preclinical research has characterised VIP's vasodilatory effects in vascular smooth muscle, its anti-inflammatory actions through immune cell VPAC receptor engagement, and its role as a circadian pacemaker signal from the suprachiasmatic nucleus in animal model systems.
In preclinical respiratory research, VIP has been extensively studied as a bronchodilator and regulator of airway smooth muscle tone, mucus secretion, and inflammatory cell activity in relevant animal model systems. Its expression in non-adrenergic non-cholinergic (NANC) neurons of the respiratory tract has been characterised in preclinical neuroanatomical and pharmacological studies.
Key Findings Reported in Preclinical Models
- Potent vasodilation and reduction of vascular smooth muscle tone characterised in preclinical vascular biology studies through VPAC receptor-mediated cAMP elevation.
- Bronchodilatory effects in preclinical respiratory model studies, with airway smooth muscle relaxation and bronchospasm attenuation documented in relevant animal models.
- Anti-inflammatory effects in preclinical immune model systems, with VIP reducing pro-inflammatory cytokine production and macrophage activation markers.
- Neuroprotective effects in preclinical models of neuroinflammation, with VIP-treated animal cohorts showing attenuated neuronal damage markers.
- Circadian rhythm regulation through VPAC2-mediated signalling in the suprachiasmatic nucleus, characterised in preclinical circadian biology research.
Introduction
VIP is one of the most pleiotropic neuropeptides characterised in preclinical research, with biological effects ranging from smooth muscle relaxation to immune regulation to circadian timekeeping. Its dual expression in the nervous system and immune cells has positioned it at the interface of neuroimmunology research, where preclinical studies have examined how neural VIP signalling influences immune cell function in inflammatory model systems.
Research Applications
- Respiratory biology research examining VIP's bronchodilatory effects and airway smooth muscle pharmacology in preclinical models.
- Neuroimmunology research studying VIP's anti-inflammatory effects through immune cell VPAC receptor engagement.
- Circadian biology research examining VPAC2-mediated signalling in the suprachiasmatic nucleus and its role in biological timekeeping.
- Neuroprotection research using VIP as a pharmacological tool to study neuropeptide-mediated anti-inflammatory protection in CNS model systems.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.